Enter Symbol
Enter Search String
Research and Markets: Warner Chilcott Ltd has a Strong Portfolio of Marketed and Pipeline Products Specialising in Women's Health and Dermatology
By: iStockAnalyst   Monday, June 09, 2008 9:48 AM

Join Blog Network
Alerts by Email
Research Articles
Stock Ranking Changes
Related RSS Feeds

Sector Feeds:

submit article

Research and Markets (http://www.researchandmarkets.com/reports/c94183) has announced the addition of "Warner Chilcott Ltd: Premium Company Profile" to their offering.

Warner Chilcott is a specialty pharmaceutical company focused on two therapeutic segments: women’s health and dermatology. The company’s predecessor company was purchased by a private equity consortium in January 2005. The company has a strong portfolio of marketed and pipeline products.

Scope of this title

- Contains corporate strategy, value chain presence and SWOT Analysis

- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

- Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights of this title

Warner Chilcott is engaged in developing, manufacturing, marketing and selling branded prescription products in women’s healthcare and dermatology. Women’s healthcare related products include Loestrin 24 FE, Ovcon 35 and Ovcon 50, Femcon FE, Estrostep FE, Femhrt and Estrace Cream and Dermatology related products include Taclonex, Dovonex and Doryx.

The company's total revenues increased at a CAGR of 34% during 2002-2006, from $235 million to $754 million. The company’s biggest contributor to revenue growth during 2002-2006 was product sales which recorded revenues of $752 million for the fiscal year 2006. The major contributors were Dovonex, Estrostep FE, Taclonex, Femhrt, and Loestrin 24 FE.

The company’s biggest contributor to sales growth out to 2010 will be the sales of Loestrin 24 FE, indicated for the prevention of pregnancy in women. Revenues from Loestrin are expected to increase at a CAGR of 59%, from $44 million in 2006 to $284 million in 2010. This represents an absolute growth of +$240 million

Key reasons to purchase this title

- Access all the important information and analysis on the company in a single report

- Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain

- Gain access to company’s adjusted five year financial data along with key ratios and market capitalization

CONTENTS:

Overview

Catalyst

Summary

Company Structure

Company Overview and Key Facts

Business Description

History

Company Financials

Stock Market Performance

P&L

Balance Sheet

Cash Flow

Products & Services

Marketed Products

Pipeline Products

Historical Product Sales

AC Forecast Product Sales

Competitors and Strategic Business Relationships

Top Competitors

Key Suppliers

Key Clients

Shareholding Structure

Strategy

Company View

Company Strategy

SWOT Analysis

Overview

Strengths

Weaknesses

Opportunities

Threats

Value Chain Analysis

Discovery and Product Development

Manufacturing

Sales

Scorecard

Overview

Scorecard Analysis

Key Employees

List of Key Employees

Key Employee Biographies

Financial and Operational Overview

Financial and Operational Overview

Appendix

Ask the analyst

Our consulting

Disclaimer

TABLES AND FIGURES ALSO INCLUDED

For more information visit http://www.researchandmarkets.com/reports/c94183.

Source: Datamonitor

Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

(Source: Business Wire )

 

 
Rate :  Rate this Commentary  


 Number of Comments (0) Post Comment
 
  
Good Rating(+1)    Bad Rating(-1)
No Data Found

 
 
  Home | Login |Research | Earnings | Scans | Chat Rooms | Charts | Submit Article | Join Blog Network | Contributors | Subscribe to RSS

copryright 2008 all rights reserved